There has been an increasing interest in finding new formulations that qualify as vaccine adjuvants, which must be safe, stable, and have the capacity to stimulate a strong immune response. In this study, a basic formulation of a water-in-oil-in-water (W/O/W) adjuvant CV13 was developed, and ginseng stem-leaf saponins (GSLS) were added as an immune booster into oil phase. The physicochemical properties of the adjuvant were tested. Furthermore, the immune activity and the adjuvant effects, as indicated by the foot-and-mouth disease virus (FMDV) antigen were evaluated. The results showed that CV13 was similar in appearance to ISA 206 and could package FMDV antigen into a stable W/O/W emulsion. The FMD vaccine prepared with CV13 alone or CV13 containing GSLS achieved pharmaceutical characteristics comparable to a vaccine prepared with ISA 206, moreover the structural stability of the CV 13 vaccine was found to be better. Mice that were immunized with the FMD vaccine prepared with CV13 containing GSLS presented a significantly higher LPBE antibody titer and splenocyte proliferation rate than those immunized with a vaccine prepared with CV13 alone (p < 0.05). In addition, there was no significant difference between the groups that were immunized with FMD vaccine prepared with CV13 containing GSLS and ISA206 in terms of cellular and humoral immune response. In this paper, CV13 containing GSLS shows excellent immunologic adjuvant effect in mice model, and this new adjuvant may provide a potential choice for FMD vaccine production in the future.

人们对寻找可以用作疫苗佐剂的新制剂的兴趣日益浓厚，这些制剂必须安全，稳定并具有刺激强烈免疫反应的能力。在这项研究中，开发了水包油包水（W / O / W）佐剂CV13的基本配方，并将人参茎叶皂苷（GSLS）作为免疫增强剂添加到油相中。测试了佐剂的理化性质。此外，评估了口蹄疫病毒（FMDV）抗原所指示的免疫活性和佐剂作用。结果表明，CV13的外观类似于ISA 206，可以将FMDV抗原包装成稳定的W / O / W乳剂。仅用CV13或含有GSLS的CV13制备的FMD疫苗就具有与ISA 206制备的疫苗相当的药物特性，此外，发现CV 13疫苗的结构稳定性更好。用含有GSLS的CV13制备的FMD疫苗免疫的小鼠比单独用CV13制备的疫苗免疫的小鼠具有更高的LPBE抗体效价和脾细胞增殖率（p <0.05）。另外，就细胞和体液免疫反应而言，用含GSLS和ISA206的CV13制备的FMD疫苗免疫的组之间没有显着差异。本文中，含有GSLS的CV13在小鼠模型中显示出优异的免疫佐剂作用，这种新佐剂可能为将来生产口蹄疫疫苗提供潜在的选择。用含有GSLS的CV13制备的FMD疫苗免疫的小鼠比单独用CV13制备的疫苗免疫的小鼠具有更高的LPBE抗体效价和脾细胞增殖率（p <0.05）。另外，就细胞和体液免疫反应而言，用含GSLS和ISA206的CV13制备的FMD疫苗免疫的组之间没有显着差异。本文中，含有GSLS的CV13在小鼠模型中显示出优异的免疫佐剂作用，这种新佐剂可能为将来生产口蹄疫疫苗提供潜在的选择。用含有GSLS的CV13制备的FMD疫苗免疫的小鼠比单独用CV13制备的疫苗免疫的小鼠具有更高的LPBE抗体效价和脾细胞增殖率（p <0.05）。另外，就细胞和体液免疫反应而言，用含GSLS和ISA206的CV13制备的FMD疫苗免疫的组之间没有显着差异。本文中，含有GSLS的CV13在小鼠模型中显示出优异的免疫佐剂作用，这种新佐剂可能为将来生产口蹄疫疫苗提供潜在的选择。就细胞和体液免疫反应而言，用含GSLS和ISA206的CV13制备的FMD疫苗免疫的组之间无显着差异。在本文中，含GSV的CV13在小鼠模型中显示出优异的免疫佐剂作用，这种新佐剂可能为将来生产口蹄疫疫苗提供潜在的选择。就细胞和体液免疫反应而言，用含GSLS和ISA206的CV13制备的FMD疫苗免疫的组之间没有显着差异。在本文中，含GSV的CV13在小鼠模型中显示出优异的免疫佐剂作用，这种新佐剂可能为将来生产口蹄疫疫苗提供潜在的选择。